Kalytera Therapeutics, Inc., (“Kalytera”) a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has entered into a technology licensing agreement (the “Agreement”) with Delivra Corp. (TSXV: DVA) (“Delivra).
Delivra is a developer of transdermal technologies that allow for the delivery of pharmaceutical and natural molecules through the skin. Under the terms of the Agreement, Delivra will license its transdermal technologies to Kalytera for the delivery of:
- Cannabidiol (“CBD”), a non-psychoactive cannabis constituent;
- KAL436/439, synthetic derivatives of CBD that have been structurally modified to enhance solubility in water for improved potency;
- KAL671, a unique synthetic fatty acid amide and an endocannabinoid-like molecule.
The agreement covers nine specific indications, including bone healing, osteogenesis imperfecta, and osteoporosis. The licensed territory is worldwide, excluding Canada. Kalytera also has the right to obtain a non-exclusive license for the delivery of cannabis plant extracts, or isolated active ingredients from the cannabis plant, for the specific indications noted above, in non-FDA regulated markets.
“Many oral medications degrade during passage through the gastrointestinal tract,” said Dr. Stuart Silverman, M.D., FACP, FACR, Co-Chair of Kalytera’s Scientific Advisory Board. “This may effect efficacy or it may cause other unwanted side effects. We were attracted to Delivra’s technologies which have demonstrated the ability to reliably deliver small molecules through the skin, with desirable pharmacokinetics.”
“Cannabinoid therapies are an expanding field of medicine with significant potential,” said Chris Schnarr, President of Delivra. “This agreement provides an opportunity for Delivra to use its proven technologies to deliver both natural CBD and Kalytera’s proprietary drug candidates through the skin. We look forward to collaborating with the Kalytera team.”
“In concert with the research now underway at Hebrew University and Tel Aviv University, securing a delivery platform and partner is an important step in advancing Kalytera’s drug candidates towards the clinic,” said Dr. Raphael Mechoulam, Ph.D., Co-Chair of Kalytera’s Scientific Advisory Board.
About Delivra Corp.
Delivra Corp. is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin, rather than via pills. Delivra manufactures and sells a growing line of natural topical creams under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada. In parallel with its consumer products business, Delivra has a mandate to license its unique, proven, and patent-pending delivery platform to global pharmaceutical companies for the transdermal delivery of third-party active ingredients to treat a broad range of conditions. Delivra is headquartered in Burlington, Ontario, Canada and has a research and development laboratory in Charlottetown, PEI, Canada. For more information, visit: www.delivracorp.com and www.livrelief.com
Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines that we believe will address large unmet market needs. Kalytera seeks to commercialize its proprietary synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone health.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.